Bronfeld Zeev Form 4 September 28, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB Washington, D.C. 20549 Number:

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

2005 Estimated average burden hours per response... 0.5

Expires:

OMB APPROVAL

3235-0287

January 31,

Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Bronfeld Zeev			2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP.OB]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 6 URI STR	,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 09/27/2011			Director Officer (give title Lelow) Director Lambda Lambd				
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year) TEL AVIV, L3 64954					l		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative S	Securi	ties Acq	quired, Disposed	of, or Benefic	ially Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactic Code (Instr. 8)	4. Securition of A. Securition (A) or Dispose (Instr. 3, 4)	posed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/27/2011			S	350,000	D	\$ 0.28	5,808,517	D	
Common Stock								781,250	I	Via DNA Biomedical Solutions Ltd. (1)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.										
Persons who respond to the collection of S information contained in this form are not								SEC 1474 (9-02)		

required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Bronfeld Zeev - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date		4. T	5.	6. Date Exer		7. Titl		8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if		ionNumber	Expiration D		Amou		Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day	(Year)	Under	, ,	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	e		Securi	ities	(Instr. 5)	Bene
	Derivative				Securities	3		(Instr.	3 and 4)		Owne
	Security				Acquired						Follo
	Ť				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						(211512
					4, and 5)						
					4, and 3)						
									Amount		
						.	.		or		
						Date	Expiration	Title	Number		
						Exercisable	Exercisable Date		of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
F-	Director	10% Owner	Officer	Other			
Bronfeld Zeev							
6 URI STREET		X					
TEL AVIV, L3 64954							

Signatures

/s/ Zeev 09/28/2011 Bronfeld **Signature of Date Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

D.N.A Biomedical Solutions Ltd. ("DNA") owns 781,250 shares of common stock of the Issuer ("Common Stock") and warrants exercisable for 273,438 shares of Common Stock. The Reporting Person holds 23.3% of DNA's outstanding share capital. The Reporting Person and Mr. Meni Mor are parties to a Voting Agreement relating to their shares of DNA, representing, in the aggregate,

approximately 46.8% of DNA's outstanding share capital. As a result of the Voting Agreement, the Reporting Person may be deemed a beneficial owner of, and to share the power to vote and dispose, the Issuer securities held by DNA. The Reporting Person disclaims beneficial ownership of any of the Issuer securities held by DNA.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2